Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG (BAYN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Bayer : Not intended for U.S. and UK Media -- Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism -- If approved, rivaroxaban 10 mg once daily will provide an additional treatment option alongside the already approved rivaroxaban 20 mg once-daily dose / Risk of recurrent thrombosis is up to 10% in the first year if anticoagulation therapy is stopped / Application to FDA supported by data from the EINSTEIN CHOICE study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2017 | 11:24pm CEST

Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism

Bayer AG published this content on 28 April 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 28 April 2017 21:24:11 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
04/28 BAYER : Not intended for U.S. and UK Media -- Rivaroxaban 10 mg Once Daily from ..
04/28 CEO WERNER BAUMANN AT THE ANNUAL STO : “We want to further strengthen Baye..
04/28 BAYER : Annual Stockholders’ Meeting -- Address by Werner Baumann -- Chair..
04/27DJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion -- Update
04/27 BAYER : CFO Dietsch to leave company in May 2018
04/27DJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion
04/25DJBAYER : 1Q 2017 -- Forecast
04/24BAYER AG : quaterly earnings release
04/24 WORLD MALARIA DAY 2017 : -- Bayer partners with Goodbye Malaria to help “E..
04/05DJVECTURA : Bayer Launches New Nebuliser in Poland; Triggers Milestone Payment
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/28 Bayer's (BAYZF) CEO Werner Baumann on Q1 2017 Results - Earnings Call Transcr..
04/27 FDA OKs expanded use of Bayer's cancer med Stivarga to include liver cancer p..
04/27 Bayer A.G. 2017 Q1 - Results - Earnings Call Slides
04/27 Bayer A.G. beats by ?0.16, beats on revenue
04/27 Bayer Q1 top line up 12%; earnings up 38%; cash flow down 36%; guidance raise..
Advertisement
Financials (€)
Sales 2017 49 597 M
EBIT 2017 9 987 M
Net income 2017 5 511 M
Debt 2017 11 401 M
Yield 2017 2,53%
P/E ratio 2017 17,53
P/E ratio 2018 16,34
EV / Sales 2017 2,21x
EV / Sales 2018 2,05x
Capitalization 98 162 M
More Financials
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 112 €
Spread / Average Target -0,65%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG13.64%106 620
JOHNSON & JOHNSON7.40%335 446
ROCHE HOLDING LTD.10.83%225 921
NOVARTIS AG2.77%203 449
PFIZER INC.4.25%201 641
MERCK & CO., INC.6.30%171 565
More Results